Provided by Tiger Fintech (Singapore) Pte. Ltd.

EyePoint

11.08
+0.06500.59%
Post-market: 11.03-0.0500-0.45%17:23 EST
Volume:1.20M
Turnover:13.60M
Market Cap:894.33M
PE:-4.09
High:12.00
Open:10.92
Low:10.86
Close:11.02
52wk High:14.91
52wk Low:3.91
Shares:80.72M
Float Shares:54.46M
Volume Ratio:0.58
T/O Rate:2.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7110
EPS(LYR):-2.3246
ROE:-73.95%
ROA:-37.79%
PB:3.64
PE(LYR):-4.77

Loading ...

BRIEF-Eyepoint Pharmaceuticals Prices Public Offering Of 11 Million Shares At $12.00 Per Share

Reuters
·
Oct 15

EyePoint Announces Pricing of Public Offering

THOMSON REUTERS
·
Oct 15

EyePoint Pharmaceuticals Inc - Prices Public Offering of 11 Mln Shares at $12.00 per Share

THOMSON REUTERS
·
Oct 15

EyePoint $150M Spot Secondary; price range $12.00-$12.50

TIPRANKS
·
Oct 15

BRIEF-Eyepoint Pharmaceuticals Inc Files For Mixed Shelf Size Not Disclosed - SEC Filing

Reuters
·
Oct 15

EyePoint Pharmaceuticals Inc - Proceeds to Advance Duravyu™ Development for Wet Amd and Dme

THOMSON REUTERS
·
Oct 15

EyePoint Announces Proposed Public Offering of Common Stock

GlobeNewswire
·
Oct 15

EyePoint Pharmaceuticals Launches Phase 3 DURAVYU Program

TIPRANKS
·
Oct 15

EyePoint Pharmaceuticals Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing

THOMSON REUTERS
·
Oct 15

EyePoint Pharmaceuticals Inc - Announces Phase 3 Program Initiation for Duravy in Diabetic Macular Edema

THOMSON REUTERS
·
Oct 15

EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema

GlobeNewswire
·
Oct 15

EyePoint reports inducement grants under NASDAQ listing rule

TIPRANKS
·
Sep 16

EyePoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Sep 16

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Sep 16

EyePoint Announces Participation at Upcoming Investor Conferences

GlobeNewswire
·
Aug 26

BRIEF-EyePoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Aug 19

EyePoint Pharmaceuticals Inc : Mizuho Raises Target Price to $28 From $26

THOMSON REUTERS
·
Aug 15

Mizuho Adjusts Price Target on EyePoint Pharmaceuticals to $28 From $26, Maintains Outperform Rating

MT Newswires Live
·
Aug 15

EyePoint Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 07

Stock Track | EyePoint Pharmaceuticals Plunges 5.88% Pre-Market on Disappointing Q2 Results and Increased Losses

Stock Track
·
Aug 06